 |
|
|
Thesis Chemistry Inc.
Contact @ Thesis Chemistry Inc.
Donald Straw, President and COO
Phone: +1 905 273 7251
Web: www.thesischemistry.com |
NEWS RELEASE…"powering pharmaceutical research and development through creative chemistry"…
THESIS CHEMISTRY APPOINTS DR. WILLIAM C. VINCEK AS CHAIRMAN OF ITS SCIENTIFIC ADVISORY BOARD
MISSISSAUGA, ONTARIO—December 16, 2002—Thesis Chemistry Inc., a provider of innovative Chemistry, Manufacturing and Control (CMC) development services to the pharmaceutical industry, has appointed Dr. William C. Vincek as Chairman of its Scientific Advisory Board (SAB).
"We are absolutely elated to have a person with such credentials, and who equally shares our commitment to highest quality customer service, lead our SAB and provide confidential technical advice on customer projects," says Dr. John R. Peterson, Chairman and Chief Executive Officer of Thesis Chemistry. "Dr. Vincek's extensive pharmaceutical background and knowledge of chemical development and regulatory guidelines will be instrumental in expediting customer projects from research scale to commercial manufacture and in developing proprietary chemical production processes."
Dr. Vincek brings approximately 20 years of industry experience in pharmaceutical development and regulatory affairs from positions at Merck Sharp and Dohme Research Laboratories, SmithKline and French Laboratories, SmithKline Beecham Pharmaceuticals, Glaxo Wellcome and Guilford Pharmaceuticals. He currently holds the position of Senior Vice President, Pharmaceutical and Chemical Development at Guilford Pharmaceuticals. Dr. Vincek received his Doctorate and Masters of Science degrees from the University of Kansas.
Thesis Chemistry powers pharmaceutical research and development through creative chemistry. Founded in 2002 as a private Canadian corporation, the Company manages and offers the highest-quality technical capabilities in support of CMC development of small-molecule drugs. Through core expertise in process and analytical chemistry and familiarity with the current regulatory requirements of drug development, Thesis Chemistry significantly reduces the time and cost of chemical development, while delivering innovative process solutions for the economical commercial manufacture of Active Pharmaceutical Ingredients (APIs). By linking specialized processing technologies and capabilities available through a network of industry partners, Thesis Chemistry brings the right technology and development capability to a project at the right time. Thesis Chemistry supports CMC development with supplies of pre-clinical and clinical API's, process design, development and optimization, analytical testing and stability, commercial API manufacture and the identification of reliable and low-cost sources of raw materials and process intermediates.
|
|
|
